• About us
• Contact

Advertisement

Document › Details

bioMérieux S.A.. (1/23/18). "Press Release: bioMérieux – Fourth-Quarter 2017 Business Review".

	Organisation	bioMérieux S.A. (Euronext: BIM)
	Group	Mérieux (Group)
	Organisation 2	BioFire Diagnostics LLC
	Today	BioFire Diagnostics Inc.
	Group	Mérieux (Group)
	Product	molecular diagnostics
	Product 2	FilmArray® PCR test (product series)
	Person	Mérieux, Alexandre (Mérieux 201712– CEO at bioMérieux before Deputy CEO before VP Industrial Microbiology)

> Excellent sales momentum in 2017 with 10.2% growth in sales, at constant exchange rates and scope of consolidation:
>> €2,288 million in sales
>> Up 8.8% as reported

> Growth underpinned by all strategic product lines, particularly BIOFIRE FILMARRAY® which accounted for more than half of growth Group-wide

> Acceleration in growth in the EMEA and Asia-Pacific regions and steady double-digit increase for the Americas

> bioMérieux expects contributive operating income before non-recurring items to be in line with its previous target of between €330 million and €345 million


Alexandre Mérieux, Chairman and Chief Executive Officer, said: "All told, 2017 was a year of remarkable growth for bioMérieux, driven by a portfolio of complementary technological solutions and a broad geographic footprint. We are particularly pleased with the performance of BIOFIRE, which confirms the success of syndromic diagnosis for infectious diseases, and with the faster-paced growth in industrial applications. These results reflect a valid business strategy that meets the needs of healthcare professionals through high medical value diagnostic solutions, and of the industry sector in order to protect consumer’s health."

Download
[ Full release at http://www.biomerieux.com/sites/corporate/files/news-event-press-release/biomerieux_pr_sales_q4_2017.pdf ]

Record changed: 2023-06-05

Advertisement

More documents for Mérieux (Group)

• [1] bioMérieux S.A.. (10/19/23). "Press Release: bioMérieux Makes Strategic Investment in Oxford Nanopore". Oxford & Marcy-l’Etoile....
• [2] bioMérieux S.A.. (4/14/23). "Press Release: Oxford Nanopore and bioMérieux to Enter into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics". Oxford & Marcy-l’Etoile....
• [3] InDevR, Inc.. (1/17/23). "Press Release: InDevR Raises $9 Million in Series B Financing and Partners with bioMérieux". Boulder, CO....
• [4] Weezion S.A.S.. (6/1/22). "Press Release: Weezion, a French MedTech Start-up, Announces Capital Investment from bioMérieux". Lyon....
• [5] bioMérieux S.A.. (3/18/22). "Press Release: bioMérieux Receives FDA 510(k) Clearance for Its VITEK MS PRIME New MALDI-TOF Mass Spectrometry Identification System". Marcy l’Étoile....
• [6] bioMérieux S.A.. (6/6/19). "Press Release: bioMérieux Increases Its Holding in Hybiome from 54% to 67%". Marcy l’Étoile....
• [7] bioMérieux S.A.. (4/24/19). "Press Release: bioMérieux – First-Quarter 2019 Business Review". Marcy l’Étoile....
• [8] bioMérieux S.A.. (4/15/19). "Press Release: “Global-PPS”, a Survey of Antibiotic Use and Bacterial Resistance in Hospitals Worldwide, Tops the 200,000 Patients". Marcy l’Étoile & Antwerp....
• [9] bioMérieux S.A.. (4/1/19). "Press Release: University of Antwerp, bioMérieux, and Wellcome Trust to Coordinate VALUE-Dx, a European Public-Private Partnership to Fight Antimicrobial Resistance through Diagnostics". Antwerp, London & Marcy l’Eoile....
• [10] bioMérieux S.A.. (3/19/19). "Press Release: Baxter and bioMérieux Announce Collaboration to Improve Identification and Treatment of Acute Kidney Injury". Deerfield, IL & Marcy l’Etoile....

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.